Found 28 articles for: "Acne Vulgaris"
Treatment Adherence in Patients With Acne Vulgaris: A Narrative Review
September 2026 | Volume 25 | Issue 9 | Original Article | 821 | Copyright © September 2026
Background: Acne vulgaris is a common dermatologic condition often requiring treatment using multiple mechanisms of action over a long time course to adequately clear symptoms. H...
Read MoreMyo-Inositol in Pregnancy: Implications for Acne Management
July 2026 | Volume 25 | Issue 7 | Original Article | 611 | Copyright © July 2026
Background: Acne vulgaris is common during pregnancy and presents unique therapeutic challenges due to fetal safety considerations and restrictions on conventional acne medicatio...
Read MoreBenzoyl Peroxide Use is Not Associated with an Increased Risk of Skin Cancer: Findings from a Multicenter TriNetX Cohort Study
July 2026 | Volume 25 | Issue 7 | Editorials | e66 | Copyright © July 2026
Efficacy and Safety of Clascoterone Cream 1% and Adapalene Gel 0.3% in Patients With Acne
June 2026 | Volume 25 | Issue 6 | Original Article | 545 | Copyright © June 2026
Background: Clascoterone cream 1% is a topical androgen receptor inhibitor approved for the treatment of acne vulgaris in patients ≥12 years of age. The American Academy of De...
Read MoreEfficacy and Safety of Clascoterone Cream 1% and Clindamycin 1.2%/Benzoyl Peroxide 5% Gel Treatment in Patients With Acne
June 2026 | Volume 25 | Issue 6 | Original Article | 537 | Copyright © June 2026
Background: Clascoterone cream 1% is a topical androgen receptor inhibitor approved to treat acne vulgaris in patients ≥12 years of age. The American Academy of Dermatology re...
Read MorePsychotherapeutic Interventions in Acne Vulgaris: A Call for Future Research
June 2026 | Volume 25 | Issue 6 | Features | e49 | Copyright © June 2026
Treating Acne Vulgaris and Scarring With Botulinum Toxin: A Systematic Review
June 2026 | Volume 25 | Issue 6 | Original Article | 508 | Copyright © June 2026
Background: Many treatments have been proposed for the treatment of acne vulgaris and acne scarring; however, few data exist regarding the efficacy of botulinum toxin A as a trea...
Read MoreMalassezia Folliculitis Presentation, Diagnosis, and Treatment: A Review of "Fungal Acne"
May 2026 | Volume 25 | Issue 5 | Original Article | 427 | Copyright © May 2026
Background: Malassezia folliculitis (MF), commonly referred to as "fungal acne" is a dermatological condition caused by colonization of the commensal fungus Malassezia, which tur...
Read MoreBenzoyl Peroxide and Malignancy Risk: A Systematic Review and Meta-analysis of Over 4 Million Patients
May 2026 | Volume 25 | Issue 5 | Editorials | e43 | Copyright © May 2026
Post-Isotretinoin Acne Management: A Pilot Survey of the American Acne and Rosacea Society Board of Directors
June 2025 | Volume 24 | Issue 6 | Editorials | e38 | Copyright © June 2025
Improvement in Skin Moisturization and Lack of Barrier Damage Following Treatment With Clascoterone Cream 1%
April 2025 | Volume 24 | Issue 4 | Original Article | 397 | Copyright © April 2025
Background: Topical medications commonly prescribed for the treatment of acne vulgaris may be limited by application-site dryness, which can result in skin barrier damage. This s...
Read MoreAn Algorithm Integrating Acneceuticals into the Management of Acne Vulgaris
April 2025 | Volume 24 | Issue 4 | Original Article | 376 | Copyright © April 2025
Background: Acne vulgaris is a common, chronic cutaneous disorder with numerous efficacious prescription and procedural treatments. Therapy, however, is hampered by medication in...
Read MoreEffective With Minimal Side Effects: A Novel Treatment Regimen for Acne Vulgaris Using Multifunctional Ingredients
December 2024 | Volume 23 | Issue 12 | Original Article | 1042 | Copyright © December 2024
Background: There are numerous over-the-counter products for treating acne, although many formulations have tolerability issues and lack the cosmetic elegance desired by adult pa...
Read MoreTreatment of Mild to Severe Acne Vulgaris With a 650-Microsecond 1064-nm Nd:YAG Laser
November 2024 | Volume 23 | Issue 11 | Original Article | 957 | Copyright © November 2024
Background: Effective treatment of acne remains a challenge to dermatologists.Objective: To evaluate the efficacy and tolerability of a 650-microsec...
Read MoreTreatment of Acne Vulgaris-Associated Post-Inflammatory Dyschromia With Combination of Non-Ablative Laser Therapy and Topical Antioxidants
September 2024 | Volume 23 | Issue 9 | Original Article | 769 | Copyright © September 2024
Acne can cause disfiguring sequelae, such as scarring, post-inflammatory erythema (PIE), and post-inflammatory hyperpigmentation (PIH). These post-inflammatory dyschromias pose a significant psyc...
Read MoreUnited Arab Emirates Consensus Recommendations for Management of Acne Vulgaris
August 2024 | Volume 23 | Issue 8 | Original Article | 653 | Copyright © August 2024
Acne in the United Arab Emirates is a common disease that causes burden to patients, has psychosocial impacts, and is associated with physical sequelae such as dyspigmentation and scarring. This ...
Read MoreIntegrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris
January 2024 | Volume 23 | Issue 1 | Original Article | 1278 | Copyright © January 2024
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged 12 years or older based on results from two identical pivotal Phase 3 trials. In...
Read MoreSeasonal Patterns in Tetracycline-Associated Hyperpigmentation Among Patients With Acne Vulgaris
November 2023 | Volume 22 | Issue 11 | Features | e9 | Copyright © November 2023
Background: Oral tetracyclines (TCNs) are commonly prescribed for acne, but they have been shown to increase the risk of hyperpigmentation, particularly in the setting of sun exp...
Read MoreLong-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
August 2023 | Volume 22 | Issue 8 | Original Article | 810 | Copyright © August 2023
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged ≥ 12 years based on results from two 12-week Phase 3 studies in patients with...
Read MoreCeramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment
June 2023 | Volume 22 | Issue 6 | Original Article | 554 | Copyright © June 2023
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
